MARX Biotech Co., Ltd. (TPEX:7731)
Taiwan · Delayed Price · Currency is TWD 4.420
-0.130 (-2.86%)
Aug 19, 2026, 10:19 AM CST
MARX Biotech Revenue
In the year 2025, MARX Biotech had annual revenue of 635.85M TWD with 2.85% growth. MARX Biotech had revenue of 326.93M in the half year ending December 31, 2025, with 42.21% growth.
Revenue
635.85M
Revenue Growth
+2.85%
P/S Ratio
4.06
Revenue / Employee
n/a
Employees
80
Market Cap
2.38B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 635.85M | 17.63M | 2.85% |
| Dec 31, 2024 | 618.23M | 328.30M | 113.24% |
| Dec 31, 2023 | 289.93M | 179.28M | 162.04% |
| Dec 31, 2022 | 110.64M | - | - |
| Dec 31, 2021 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| PharmaEssentia | 20.75B |
| Wellell | 2.50B |
| Syngen Biotech | 2.05B |
| A Plus Biotechnology | 887.93M |
| Medimaging Integrated Solution | 682.01M |
| Johnson Chemical Pharmaceutical Works | 569.57M |
| Caliway Biopharmaceuticals | 29.39M |
| Pell Bio-Med Technology | 28.93M |